Nine Square Therapeutics Appoints Robert Paul as CEO

SOUTH SAN FRANCISCO, Calif., Jan. 11, 2022 -- (Healthcare Sales &Marketing Network) -- Nine Square Therapeutics, a biotechnology company applying computational chemistry and machine-learning enabled cell profiling to discover and develop novel small-mole... Biopharmaceuticals, Neurology, Personnel Nine Square Therapeutics, Parkinson's disease, amyotrophic lateral sclerosis
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news

Related Links:

Drug Metab Rev. 2022 Jan 17:1-17. doi: 10.1080/03602532.2022.2029475. Online ahead of print.ABSTRACTNeurodegenerative diseases correspond to overly complex health disorders that are driven by intersecting pathophysiology that are often trapped in vicious cycles of degeneration and cognitive decline. The usual diagnostic route of these diseases is based on postmortem examination that involves identifying pathology that is specific to the disease in the brain. However, in such cases, accurate diagnosis of the specific disease is limited because clinical disease presentations are often complex that do not easily allow to disc...
Source: Drug Metabolism Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Trends Neurosci. 2022 Jan 13:S0166-2236(21)00252-6. doi: 10.1016/j.tins.2021.12.004. Online ahead of print.ABSTRACTThe understanding of lysosomes has come a long way since the initial discovery of their role in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle positioned at the crossroads of cell signaling, transcription, and metabolism. Underscoring its importance is the observation that, in addition to rare monogenic lysosomal storage disorders, genes regulating lysosomal function are implicated in common sporadic neurodegenerative diseases, including Alzheimer's disease (AD), Parkins...
Source: Trends in Neurosciences - Category: Neuroscience Authors: Source Type: research
Drug Metab Rev. 2022 Jan 17:1-17. doi: 10.1080/03602532.2022.2029475. Online ahead of print.ABSTRACTNeurodegenerative diseases correspond to overly complex health disorders that are driven by intersecting pathophysiology that are often trapped in vicious cycles of degeneration and cognitive decline. The usual diagnostic route of these diseases is based on postmortem examination that involves identifying pathology that is specific to the disease in the brain. However, in such cases, accurate diagnosis of the specific disease is limited because clinical disease presentations are often complex that do not easily allow to disc...
Source: Drug Metabolism Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Trends Neurosci. 2022 Jan 13:S0166-2236(21)00252-6. doi: 10.1016/j.tins.2021.12.004. Online ahead of print.ABSTRACTThe understanding of lysosomes has come a long way since the initial discovery of their role in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle positioned at the crossroads of cell signaling, transcription, and metabolism. Underscoring its importance is the observation that, in addition to rare monogenic lysosomal storage disorders, genes regulating lysosomal function are implicated in common sporadic neurodegenerative diseases, including Alzheimer's disease (AD), Parkins...
Source: Trends in Neurosciences - Category: Neuroscience Authors: Source Type: research
Drug Metab Rev. 2022 Jan 17:1-17. doi: 10.1080/03602532.2022.2029475. Online ahead of print.ABSTRACTNeurodegenerative diseases correspond to overly complex health disorders that are driven by intersecting pathophysiology that are often trapped in vicious cycles of degeneration and cognitive decline. The usual diagnostic route of these diseases is based on postmortem examination that involves identifying pathology that is specific to the disease in the brain. However, in such cases, accurate diagnosis of the specific disease is limited because clinical disease presentations are often complex that do not easily allow to disc...
Source: Drug Metabolism Reviews - Category: Drugs & Pharmacology Authors: Source Type: research
Trends Neurosci. 2022 Jan 13:S0166-2236(21)00252-6. doi: 10.1016/j.tins.2021.12.004. Online ahead of print.ABSTRACTThe understanding of lysosomes has come a long way since the initial discovery of their role in degrading cellular waste. The lysosome is now recognized as a highly dynamic organelle positioned at the crossroads of cell signaling, transcription, and metabolism. Underscoring its importance is the observation that, in addition to rare monogenic lysosomal storage disorders, genes regulating lysosomal function are implicated in common sporadic neurodegenerative diseases, including Alzheimer's disease (AD), Parkins...
Source: Trends in Neurosciences - Category: Neuroscience Authors: Source Type: research
Clin Pharmacol Ther. 2022 Jan 16. doi: 10.1002/cpt.2528. Online ahead of print.ABSTRACTGlobal regulatory agencies have transformed their approach to approvals in their processes for formal review of the safety and efficacy of new drugs. Opportunities for innovation have expanded because of the COVID-19 pandemic. Several regulatory-led initiatives have progressed rapidly during the past year including patient-focused drug development, model-informed drug development, Real World Evidence, and complex innovative trial designs. Collectively, these initiatives have accelerated the rate of approvals. Despite demands to focus on ...
Source: Clinical Pharmacology and Therapeutics - Category: Drugs & Pharmacology Authors: Source Type: research
Adv Exp Med Biol. 2021;1339:415-422. doi: 10.1007/978-3-030-78787-5_52.ABSTRACTMany types of amyloidoses are pathologically characterized by the deposition of amyloid, which is comprised of fibrils formed by abnormally aggregated proteins, in various peripheral tissues and the central nervous system (CNS). Neurodegenerative disorders, such as Alzheimer disease (AD), Parkinson disease (PD), frontotemporal dementia (FTD), and amyotrophic lateral sclerosis (ALS), are well-known CNS amyloidoses that are characterized by amyloid deposition both inside and outside of cells. The amyloidogenic proteins of each disease have distinc...
Source: Advances in Experimental Medicine and Biology - Category: Research Authors: Source Type: research
The cycad neurotoxin beta-methylamino-l-alanine (L-BMAA), one of the environmental trigger factor for amyotrophic lateral sclerosis/Parkinson-dementia complex (ALS/PDC), may cause neurodegeneration by disrupting ...
Source: Cell Communication and Signaling - Category: Molecular Biology Authors: Tags: Research Source Type: research
This study aims to examine the association between metal/metalloid levels and ALS onset by evaluating blood cadmium (Cd), lead (Pb), Cu, Zn, calcium (Ca), magnesium (Mg), and iron (Fe) levels in controls and sporadic ALS patients from North Western China. We report that Cu and Fe levels are found at higher levels in ALS patients compared to the controls. Spinal and bulbar onset patients show significant difference in Ca levels. Moreover, Cd, Pb, Cu, and Ca levels are positively correlated with high disease severity. Results from this study may provide new insights for understanding not only the role of metal/metalloids in ...
Source: Neurotoxicology - Category: Neurology Authors: Source Type: research
More News: ALS | Biotechnology | Brain | Chemistry | Learning | Marketing | Neurology | Parkinson's Disease | Pharmaceuticals | Universities & Medical Training